Evidence map›Paper›PMID 35162728›Full record

ArticleInternational journal of environmental research and public health2022

High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities.

Emilia M Jalil, Thiago S Torres, Claudia C de A Pereira, Alessandro Farias, Jose D U Brito, Marcus Lacerda, Daila A R da Silva, Nickols Wallys, Gabriela Ribeiro, Joyce Gomes and 8 more

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Utilizing Machine Learning for Predicting PrEP Use Status Among Sexual and Gender Minority Young Adults.Prevention science : the official journal of the Society for Prevention Research · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir Cohort.International journal of sexual health : official journal of the World Association for Sexual Health · 2025
    Article
  14. South African harm reduction guideline for chemsex.Southern African journal of HIV medicine · 2025
    Article
  15. Article
  16. The Syndemic of HIVHIV specialist · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Emilia M JalilInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.ORCID 0000-0001-6017-5660
Thiago S TorresInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.ORCID 0000-0002-2557-601X
Claudia C de A PereiraEscola Nacional de Saúde Pública Sérgio Arouca ENSP-Fiocruz, Rio de Janeiro 21041-210, Brazil.
Alessandro FariasCentro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP), Salvador 40100-010, Brazil.
Jose D U BritoHospital Dia Asa Sul, Brasília 70351-580, Brazil.
Marcus LacerdaFundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT), Manaus 69040-000, Brazil.
Daila A R da SilvaCentro de Testagem Aconselhamento (CTA) Santa Marta, Secretaria Municipal de Saúde de Porto Alegre, Porto Alegre 90010-040, Brazil.
Nickols WallysInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Gabriela RibeiroInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Joyce GomesFundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT), Manaus 69040-000, Brazil.
Thiffany OdaraCentro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP), Salvador 40100-010, Brazil.
Ludymilla SantiagoHospital Dia Asa Sul, Brasília 70351-580, Brazil.
Sophie NouveauCentro de Testagem Aconselhamento (CTA) Santa Marta, Secretaria Municipal de Saúde de Porto Alegre, Porto Alegre 90010-040, Brazil.
Marcos BenedettiInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Cristina PimentaDepartamento de Condições Crônicas e Infecções Sexualmente Transmissíveis, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília 70719-040, Brazil.
Brenda HoaglandInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil.
Fundação Oswaldo Cruz · BRFundação de Medicina Tropical · BRSecretaria Municipal de Saúde · BREscola Nacional de Saúde Pública · BRMinistério da Saúde · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: We aimed to estimate sexualized drug use (SDU) prevalence and its predictors among sexual and gender minorities. (2) Methods: We used an online and on-site survey to enroll sexual/gender minorities people between October-December/2020, and multivariate logistic regression to obtain SDU correlates. (3) Results: We enrolled 3924 individuals (280 transgender women [TGW], 3553 men who have sex with men [MSM], and 91 non-binary), 29.0% currently on pre-exposure prophylaxis (PrEP). SDU prevalence was 28.8% (95% confidence interval [CI] 27.4-30.2). TGW had 2.44-times increased odds (95%CI 1.75-3.39) of engaging in SDU compared to MSM, regardless of PrEP use. PrEP use (aOR 1.19, 95%CI 1.00-1.41), South/Southeast region (aOR 1.26, 95%CI 1.04-1.53), younger age (18-24 years: aOR 1.41, 95%CI 1.10-1.81; 25-35 years: aOR 1.24, 95%CI 1.04-1.53), white race/color (aOR 1.21, 95%CI 1.02-1.42), high income (aOR 1.32, 95%CI 1.05-1.67), binge drinking (aOR 2.66, 95%CI 2.25-3.14), >5 sexual partners (aOR 1.88, 95%CI 1.61-2.21), condomless anal sex (aOR 1.49, 95%CI 1.25-1.79), self-reported sexually transmitted infection (aOR 1.40, 95%CI 1.14-1.71), and higher perceived HIV-risk (aOR 1.37, 95%CI 1.14-1.64) were associated with SDU. (4) Conclusions: TGW had the highest SDU odds. SDU may impact HIV vulnerability among key populations and should be addressed in HIV prevention approaches.

Indexed as

HIV InfectionsPharmaceutical PreparationsPre-Exposure ProphylaxisSexual and Gender MinoritiesTransgender PersonsAdolescentAdultCross-Sectional StudiesFemaleHomosexuality, MaleHumansMaleSexual BehaviorYoung AdultPharmaceutical PreparationsBrazilchemsexLatin Americamen who have sex with mensexual and gender minoritiestransgender women

Identifiers

PMID35162728
PMCPMC8835457
OpenAlexW4210443746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.